Ozempic, a medication originally created to treat diabetes, also has a reputation as a weight loss miracle drug. According to Goldman Sachs, the popular medication, along with other weight-loss drugs in the glucagon-like peptide-1 class (GLP-1), could help lift the U.S. economy in the next few years.
While the purchase of these drugs could contribute significantly to the economy, more surprising factors like employability rates and household shopping routines could be affected too.
Get instant access to hundreds of discounts
Over 50? Join AARP today— because if you’re not a member you could be missing out on huge perks like discounts on travel, dining, and even prescriptions.
Get 25% off membership — just $15 for your first year with auto-renewal — and a free gift if you join today.
How Ozempic could help the workforce
/images/2023/03/01/old-man-saving-pennies-in-jar-with-health-label.jpeg)
Ozempic and other GLP-1 drugs could potentially impact the overall health of the workforce — ultimately boosting the economy.
Goldman Sachs claims that poor health conditions like sickness and disability among employees can hurt economic growth due to the limited availability of workers and hours/days worked.
Goldman Sachs analysts, led by Jan Hatzius, said, "The main reason we see meaningful upside from healthcare innovation is that poor health imposes significant economic costs. There are several channels through which poor health weighs on economic activity that could diminish if health outcomes improve."
If illnesses and disabilities did not affect productivity in the workforce, the gross domestic product (GDP) could increase by as much as 10%.
How much the economy could be impacted
/images/2024/02/15/computer-display-with-a-gdp-word.jpg)
Goldman Sachs analysts predict that the use of weight-loss drugs could raise the country's GDP by 1% within the next decade– which is about $360 billion per year.
More drug companies are also looking to enter the market and invite future competition with different variations of the popular weight-loss drugs. Currently, Novo Nordisk and Eli Lilly are the pharmaceutical front-runners for producing Ozempic and other GLP-1s.
According to an estimate from JPMorgan, the weight-loss drug market has the potential to reach $100 billion by 2030.
Other economic impacts of GLP-1s
/images/2023/06/15/senior-couple-paying-for-grocery-using-smartphone.jpeg)
Unexpected areas of the economy, like grocery shopping, may be impacted by households that use GLP-1 drugs. In a survey from Numerator, households using GLP-1s decreased monthly grocery spending by as much as 6% to 9% compared to those who don't use them.
In the survey, they found that the types of products normally purchased have also shifted. Purchases of items like snacks, baked goods, and ice cream decreased, whereas purchases of healthy foods like vegetables, fish, and yogurt increased.
Large retailers like Walmart have already begun to notice the change in shopping behaviors.
Novo Nordisk's CEO Lars Fruergaard Jorgensen said he received calls from various food company representatives who are on alert about the drug's potential effects on their bottom lines.
Bottom line
/images/2023/06/20/man-preparing-semaglutide-ozempic-injection-to-check-blood-sugar-levels.jpeg)
By 2028 up to 70 million Americans could be taking weight-loss drugs like Ozempic.
With several signs pointing to an economic boost, other weight-loss drug variations may go to market soon. These drugs are also being tested to see if they are effective in treating everything from alcohol addiction to dementia.
Up To 5% Cash Back
Discover it® Cash Back
Current Offer
Discover will match all the cash back you’ve earned at the end of your first year.
Annual Fee
$0
Rewards Rate
Earn 5% cash back on everyday purchases at different places you shop each quarter like grocery stores, restaurants, gas stations, and more, up to the quarterly maximum when you activate. Plus, earn unlimited 1% cash back on all other purchases.
Benefits
- $0 annual fee
- Intro APR on purchases and balance transfers
Drawbacks
- Requires you to activate the highest-earning category each quarter
- Not accepted as widely overseas as Visa or Mastercard
- INTRO OFFER: Unlimited Cashback Match for all new cardmembers–only from Discover. Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300.
- Earn 5% cash back on everyday purchases at different places you shop each quarter like grocery stores, restaurants, gas stations, and more, up to the quarterly maximum when you activate. Plus, earn unlimited 1% cash back on all other purchases.
- Redeem your rewards for cash at any time.
- Apply and you could get a decision in as little as 60 seconds. No annual fee.
- Start shopping and earning rewards in minutes with your digital card, before your physical card arrives in the mail, if eligible.
- Get a 0% intro APR for 15 months on purchases. Then 18.24% to 27.24% Standard Variable Purchase APR applies, based on credit worthiness.
- Terms and conditions apply.
Subscribe Today
Learn how to make an extra $200
Get vetted side hustles and proven ways to earn extra cash sent to your inbox.